Anavex Life Sciences Corp.(NASDAQ : AVXL)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
Loading AVXL News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.04%||68.55||0.9%||$505.54m|
|REGN||Regeneron Pharmaceuticals, Inc.||5.97%||388.49||2.7%||$332.95m|
|ALXN||Alexion Pharmaceuticals, Inc.||0.69%||127.78||1.9%||$250.96m|
|VRTX||Vertex Pharmaceuticals Incorporated||0.75%||118.30||1.9%||$235.75m|
|NBIX||Neurocrine Biosciences, Inc.||-0.36%||53.40||5.3%||$114.24m|
|BMRN||BioMarin Pharmaceutical Inc.||-0.40%||95.88||4.5%||$113.09m|
|KITE||Kite Pharma, Inc.||-0.68%||82.08||16.6%||$94.29m|
|A||Agilent Technologies, Inc.||-0.70%||55.04||1.5%||$93.33m|
|SRPT||Sarepta Therapeutics, Inc.||4.44%||36.26||19.8%||$82.73m|
Anavex Life Sciences Corp. engages in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. It's lead compound, ANAVEXTM 2-73, is being developed to treat Alzheimer's disease, Parkinson's disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.